First in human PET study of Flutriciclamide (18F-GE180) a novel third generation marker of Human Translocator Protein

Trial Profile

First in human PET study of Flutriciclamide (18F-GE180) a novel third generation marker of Human Translocator Protein

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs GEH 120714 (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Diagnostic use; First in man
  • Most Recent Events

    • 16 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top